Involvement of JAK/STAT signaling in the effect of cornel iridoid glycoside on experimental autoimmune encephalomyelitis amelioration in rats.

Authors: Yin, L  Chen, Y  Qu, Z  Zhang, L  Wang, Q  Zhang, Q  Li, L 
Citation: Yin L, etal., J Neuroimmunol. 2014 Sep 15;274(1-2):28-37. doi: 10.1016/j.jneuroim.2014.06.022. Epub 2014 Jun 28.
Pubmed: (View Article at PubMed) PMID:25012120
DOI: Full-text: DOI:10.1016/j.jneuroim.2014.06.022

In the present study, we investigated the therapeutic benefit of cornel iridoid glycoside (CIG), the main component extracted from Cornus officinalis, in experimental autoimmune encephalomyelitis (EAE) rats. CIG was intragastrically administered daily after EAE initiation for 20days and reduced disease severity, incidence, disease onset and ongoing paralysis. Histopathological staining showed that CIG could reduce T cell entry to the central nervous system and microglia activation, increased brain-derived neurotrophic factor (BDNF) expression and mature oligodendrocytes, and decreased oligodendrocyte progenitor cells (OPCs). Also, CIG treatment inhibited brain JAK/STAT1/3 and reduced proinflammatory cytokines. CIG might be a novel potential therapeutic agent for multiple sclerosis (MS).


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 11533939
Created: 2016-09-13
Species: All species
Last Modified: 2016-09-13
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.